Nephrologist Allan Kavalich, MD, to Discuss Improvements in Infections Associated With Peritoneal Dialysis Catheters With Use of NeutroPhase - Pure 0.01% Hypochlorous Acid Solution
EMERYVILLE, Calif., Feb. 7, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic anti-microbial products, today announced that NovaBay will have a booth at the Annual Dialysis Conference, held February 8-11, 2014 in Atlanta, GA. Dr. Allan G. Kavalich, a nephrologist based in San Bernardino, CA will be present in the NovaBay booth and available to answer questions on the research he conducted with NeutroPhase®* in 2013. NeutroPhase is a 0.01% pure hypochlorous acid in saline with no bleach impurities, unlike Dakin and other Dakin-like solutions. In laboratory testing NeutroPhase has been shown to be 100-fold more antimicrobial than Dakin and 100-fold safer than Dakin.
Dr. Kavalich previously presented the poster entitled: "Pure 0.01% Hypochlorous Acid Solution Shows Improvement in the Infections Associated with Peritoneal Dialysis Catheters" at the American Society of Nephrology meeting in Atlanta in November 2013. The key findings from the poster are that there is clear utility for the use of NeutroPhase for preventing bacterial and yeast infections associated with the use of peritoneal dialysis catheters. It also showed that there appears to be no emergence of resistant organisms after treatment with NeutroPhase in these cases. Moreover, NeutroPhase was useful as an irrigant in his cases involving multi-resistant organisms and relapsing infections. Based on the positive findings from these cases, Dr. Kavalich is working on a manuscript for publication. The full ASN poster can be accessed here.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing topical non-antibiotic antimicrobial products.
NeutroPhase® is a 510(k)-cleared wound cleanser and is intended for use under the supervision of healthcare professionals for cleansing and removal of foreign material, including: microorganisms and debris from wounds; cleaning minor cuts, minor burns, superficial abrasions, and minor irritations of the skin; as well as moistening absorbent wound dressings. It is also intended for moistening and debriding acute and chronic dermal lesions, such as: Stage I-IV pressure ulcers, stasis ulcers, leg ulcers, diabetic foot ulcers, post surgical wounds, first and second degree burns, as well as grafted and donor sites.
NeutroPhase is a 0.01% pure hypochlorous acid in saline (with no bleach impurities, which are often present in Dakin and Dakin-like solutions which do not impede the growth of fibroblasts). FDA has not reviewed NovaBay's data with respect to anti-toxin activity of NeutroPhase in in vitro experiments. In in vitro laboratory models, NeutroPhase has shown to be fast-acting against bacteria, biofilm and toxins. More information on NeutroPhase and how to purchase it at: www.neutrophase.com.
Interested in Ordering NeutroPhase?
NeutroPhase is marketed in the United States by Principal Business Enterprises, Inc. (PBE). Physicians and Nurses interested in ordering samples call (888) 980-9702 or go to: http://www.neutrophase.com/contact.html.
NeutroPhase Partnering Opportunities are Available
If interested in developing commercial partnerships for marketing NeutroPhase outside of the U.S., China and Southeast Asia, please contact Roy Wu, Senior Vice President, Business Development at: http://novabay.com/contact-business-development.
This release contains forward-looking statements and opinions, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the general use of antibiotics in the United States and NovaBay's possible effect on that use. The words "potentially," "think" and "believe" are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay's progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website
|NovaBay Pharmaceuticals Contacts|
|Thomas J. Paulson|
|Chief Financial Officer|
|Contact T. Paulson|
|Director, Investor Relations and Corporate Communications|
|NovaBay Pharmaceuticals, Inc.|
|Contact A. Kapor|